![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00119626 |
This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.
Condition | Intervention | Phase |
---|---|---|
Cerebral Stroke Ischemic Attack, Transient |
Drug: NXY-059 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | SAINT I (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke. |
Estimated Enrollment: | 1700 |
Study Start Date: | June 2003 |
Study Completion Date: | February 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Sweden | |
Research Site | |
Södertälje, Sweden | |
United Kingdom | |
Research Site | |
Glasgow, United Kingdom |
Study Director: | AstraZeneca NXY-059 Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | SA-NXY-0006, 0006, SAINT I |
Study First Received: | July 6, 2005 |
Last Updated: | March 18, 2009 |
ClinicalTrials.gov Identifier: | NCT00119626 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Stroke, Acute Cerebrovascular Stroke |
Ischemic Attack, Transient Antioxidants Cerebral Infarction Stroke Vascular Diseases Central Nervous System Diseases Disufenton sodium |
Ischemia Cardiovascular Agents Brain Diseases Cerebrovascular Disorders Brain Ischemia Brain Infarction Infarction |
Ischemic Attack, Transient Antioxidants Molecular Mechanisms of Pharmacological Action Cerebral Infarction Physiological Effects of Drugs Stroke Nervous System Diseases Vascular Diseases Disufenton sodium Central Nervous System Diseases Cardiovascular Agents |
Ischemia Brain Diseases Protective Agents Cerebrovascular Disorders Pharmacologic Actions Pathologic Processes Therapeutic Uses Brain Ischemia Cardiovascular Diseases Brain Infarction |